Mineralys Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Trade Mineralys Therapeutics 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About MLYS
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease.
CEOJon Congleton
CEOJon Congleton
Employees51
Employees51
HeadquartersRadnor, Pennsylvania
HeadquartersRadnor, Pennsylvania
Founded2019
Founded2019
Employees51
Employees51
MLYS Key Statistics
Market cap3.09B
Market cap3.09B
Price-Earnings ratio-10.98
Price-Earnings ratio-10.98
Dividend yield—
Dividend yield—
Average volume875.93K
Average volume875.93K
High today$40.48
High today$40.48
Low today$38.52
Low today$38.52
Open price$39.01
Open price$39.01
Volume894.27K
Volume894.27K
52 Week high$44.80
52 Week high$44.80
52 Week low$8.24
52 Week low$8.24
Analyst ratings
88%
of 8 ratingsBuy
87.5%
Hold
12.5%
Sell
0%
People also own
Based on the portfolios of people who own MLYS. This list is generated using Robinhood data, and it’s not a recommendation.